Artelo Biosciences, Inc.

09/07/2022

Our CSO Andy Yates was recently on the Transformation in Trials podcast hosted by Ivanna Rosendal and Sam Parnell... check it out!

Sam and Ivanna speak to Andy Yates, the Chief Scientific Officer for Artelo Biosciences about how they are tapping into the potential of the endocannabinoid system to increase treatment results for oncology patients. Artelo Biosciences has departe...

09/07/2022

$ARTL to Present at the 24th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company…...

09/06/2022

https://artelobio.com/pipeline/art27-13/

08/26/2022

$ARTL is pleased to report we received notice from Nasdaq on achieving continued listing requirement with minimum bid price. We are well-capitalized with last reported cash over $20M and look forward to upcoming milestones.

08/25/2022

Come visit Artelo's updated website where you can find presentations, new videos on the CAReS study, and learn why there is hope for people living with cancer anorexia. Also, read about the science platforms that back our novel development pipeline
https://artelobio.com/

08/16/2022

$ARTL Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5
https://ir.artelobio.com/news-events/press-releases/detail/90/artelo-biosciences-reports-positive-pre-clinical-results
.12

Recently Published Findings Support Further Development in Anxiety-Related Disorders SOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) --…...

08/15/2022

$ARTL is pleased to present part 2 of our ART27.13 video series! Watch to learn more about our Cancer Appetite Recovery Study (CAReS) from Principal Investigator Dr. Barry Laird and CSO Dr. Andy Yates
https://youtu.be/xkLWk7Tgz8E
.13

Artelo's Phase 1b/2a CAReS trial is assessing the safety and efficacy of ART27.13, a dual cannabinoid agonist program for cancer-related anorexia and weight ...

08/09/2022

$ARTL Reports Second Quarter 2022 Financial Results and Provides Business Update
https://ir.artelobio.com/news-events/press-releases/detail/89/artelo-biosciences-reports-second-quarter-2022-financial

CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced…...